Objective: To systematically review the evidence regarding rehabilitation treatments in multiple sclerosis (MS).
Multiple sclerosis (MS) affects approximately 400,000 individuals in the United States and is a leading cause of disability in young adults. 1-5 Rehabilitation interventions are frequently used clinical strategies for improving or maintaining functional status. 6 This systematic review addresses the following questions in MS:
1. Does outpatient or inpatient comprehensive multidisciplinary rehabilitation minimize impairment, reduce disability, or improve health-related quality of life (HRQL)? 2. Do supervised outpatient or inpatient physical therapy (PT), physical training, or physical exercise programs minimize impairments, reduce disability, or improve HRQL?
3. Do other specific therapy techniques minimize impairment, reduce disability, or improve HRQL? 4. Do energy efficiency/conservation techniques, specialty devices, or educational programs affect function or HRQL?
DESCRIPTION OF THE ANALYTIC PROCESS The American Academy of Neurology (AAN) assembled an expert panel after review of conflict of interest statements to develop this document, following the processes documented in the 2004 AAN manual. 7 A medical research librarian helped perform a comprehensive literature search, and the authors selected articles. At least 2 authors rated each article independently of each other (AAN therapeutic classification scheme). Panelists reviewed 5,464 abstracts and selected 491 articles for full-text review. Ultimately, we rated 142 articles according to the 2004 AAN scheme for classifying therapeutic articles (appendix e-4 on the Neurology ® Web site at Neurology.org). 7 We excluded studies lacking a control group (because of a resulting high risk of bias), involving fewer than 20 participants, or evaluating pharmaceutical efficacy, electrical simulation, pain as the sole outcome, or an instrument's psychometrics. We classified each of the outcome measure scales as an objective measure or a patient-reported measure (table e-1). Several studies evaluated multiple outcome measures, some objective and others not, with or without a blinded evaluator. Thus, a single study could have different classifications depending on the outcome measure considered. We have clarified this by adding the study class in parenthesis for each outcome. When multiple studies used the same data, we analyzed the studies together. Except for the specified primary outcome in the first publication, we considered all outcomes as secondary, unless the authors specified multiple primary outcomes in successive publications; in this latter case, we analyzed the studies as lacking a specified primary outcome. Unless subgroup analyses were available for specific MS subtypes, we restricted conclusions to the overall MS group. We applied Bonferroni corrections as needed. Tables e-2 (1 Class III study, data for control group not provided). 21 Do supervised outpatient or inpatient PT, physical training, or physical exercise programs minimize impairments, reduce disability, or improve HRQL? Outpatient and inpatient PT and home PT. One study (Class I for objective outcomes, Class III for patient-reported outcomes) (n 5 40, 48 weeks) examined home PT, outpatient PT, and no therapy in participants with MS (type unspecified, EDSS 4-6.5) able to walk $5 meters with or without aid in a crossover study. 22 All participants were randomly allocated to 1 of the study groups for 8 weeks and then to the other 2 study groups for 8 weeks each. Each crossover arm was separated by an 8-week washout period. The primary outcome of disability, Rivermead Mobility Index, improved 23 One study (Class II for objective outcomes, Class III for patient-reported outcomes, n 5 50, 3 weeks, relapsing-remitting MS [RRMS], SPMS, PPMS, EDSS 3-6.5) randomized participants either to twice-daily individualized inpatient physical exercise followed by home exercises or home exercises only. 27 The coprimary disability outcomes (EDSS and FIM motor domain) and HRQL (SF-36) were assessed at baseline and 3, 9, and 15 weeks. EDSS results (impairment/disability) did not change. The changes in EDSS scores clustered closely around zero in both groups at all time points (data not provided). FIM motor scores (disability, measured as a composite of the FIM self-care, locomotion, and transfer subscales) improved (3 weeks: intervention group and control group improved $2 steps by 48% and 9%, respectively, p 5 0.004; 9 weeks: intervention group and control group retained the 3-week gains by 44% and 4.5%, respectively, p 5 0.001; 15 weeks: no difference) (EDSS and FIM may have been inconsistent because of differences in sensitivity to short-term functional changes). After Bonferroni adjustment, the improvement in the FIM motor domain subscale scores was significant at 3 weeks (mean change 0.62, 95% CI 0.28-0.96). The SF-36 mental composite improved at 9 weeks (mean change 10.1, 95% CI 3.05-17.2).
Resistance training and aerobic exercise programs. No Class I or Class II studies were available.
Gait and balance training. A Class I study (n 5 35, 3 weeks, RRMS, SPMS, PPMS, EDSS 6-7.5) examined the effect of robot-assisted gait training (RAGT). 28 Participants admitted for multimodal inpatient rehabilitation were randomized to receive an additional 15 sessions of RAGT (n 5 19) or conventional walking training (CWT) over 3 weeks. The primary outcome was 20-meter timed walking velocity. The mean change in the RAGT group was 0.11 (95% CI 0.02-0.28), and in the CWT group, 0.07 (95% CI 0.0-0.14). ES difference between groups was 0.7 (95% CI 20.089 to 1.489). Other outcomes were 6-minute walking distance, stride length, and knee extensor strength. After 3 weeks, no statistical difference was seen between groups for these outcome measures, but the study lacked precision to detect a difference (wide CIs for the ES change in the primary outcome, the 20-minute timed walk).
A Class II study evaluated balance training (n 5 44, RRMS, SPMS, PPMS, 3 weeks). 29 Participants were randomized to receive motor and sensory balance training (group 1), motor balance training only (group 2), or conventional therapy (group 3). After treatment, the relative frequencies of participants who had one or more falls were 1 (5%) in group 1, 1 (10%) in group 2, and 3 (25%) in group 3 (corrected p , 0.005). The small number of events in each group made interpretation difficult. Static balance, measured by the Berg Balance Scale (BBS), 30 32 and self-confidence (Activities-specific Balance Confidence Scale) 33 did not change, but the study lacked precision for detecting a benefit for these outcomes (wide CIs).
Community/group programs. No Class I or Class II studies were available.
Conclusions.
1. Weekly home or outpatient PT for 8 weeks probably is effective for improving balance, disability, and gait in individuals with MS (type unspecified) who are able to walk $5 meters with/without an assistive device (1 Class I study). 22 These programs probably are ineffective for improving upper extremity dexterity (1 Class I study). 22 Data are inadequate to support/refute the use of these programs for improving self-reported falls/mobility, depression, or anxiety (1 study rated Class III for subjective outcomes). 22 2. Three weeks' worth of individualized inpatient exercise followed by home exercises for 15 weeks possibly is effective for reducing disability (RRMS, PPMS, SPMS, EDSS 3.0-6.5) (1 Class II study). 27 Data are inadequate to support/refute the use of this regimen for improving HRQL (1 study rated Class III for subjective outcomes). 27 
Three weeks' worth of motor and sensory balance
training or motor balance training possibly is effective for improving static and dynamic balance, and motor balance training possibly is effective for improving static balance (RRMS, SPMS, PPMS) (1 Class II study). 29 Data are inadequate to support/refute the use of this regimen for reducing falls or self-reported disability and handicap, or for improving confidence in balance skills (small numbers of falls in each group, making interpretation difficult; insufficient precision for subjective outcomes). 29 Clinical context. Although evidence that exercise programs improve MS-related outcomes is unavailable, the benefits of exercise in the general population and the extent of MS-related disability are useful for clinicians to consider when counseling patients with MS regarding exercise.
Do other specific therapy techniques minimize impairment, reduce disability, or improve HRQL? A Class II randomized trial conducted in 2 phases compared balancebased torso weighting (BBTW, involving the addition of weights to the torso or extremities to assist in coordinated movement) with no intervention and then randomized the control group to receive BBTW or standard weight placement (SWP, 1.5% body weight 3.7] , corrected p 5 0.2), but the study was underpowered to detect a significant difference, and the degree of change is of uncertain clinical significance. All other analyses showed no difference between groups but lacked sufficient precision to exclude an effect.
One study e11 assessed the effect of a home program of breathing-enhanced upper extremity exercises (as compared with no intervention e8 ) on respiratory function (n 5 40, RRMS, PPMS, SPMS, EDSS 4.51 6 1.55, 6 weeks). This study is Class II for the objective outcomes of walking speed (6MW), disability (EDSS), and spirometry measures and Class III for patientreported outcomes ( Another study evaluated the effect of an inspiratory muscle training program as compared with no intervention (n 5 46, 10 weeks, RRMS, SPMS, PPMS, EDSS 2-6.5). The outcomes were multiple pulmonary function variables (Class II, objective) and fatigue (Fatigue Severity Scale) (Class III, patient-reported). PI max improved (mean change [95% CI], treatment group 23.5 [8.92-38 .08], control 20.7 [217.08 to 15.68], corrected p , 0.008), but precision for the other outcomes was insufficient to exclude a possible benefit. e14
Conclusions. The available evidence as judged by the criteria applied here precludes formulation of recommendations with regard to the effectiveness of rehabilitation therapy in specific MS subtypes, or in milder disability from progressive MS, or immediately after MS relapse. The benefit is unknown beyond 12 weeks in moderate disability from progressive MS. Studies either excluded individuals who had a recent exacerbation or failed to mention timing of relapse in relation to the rehabilitation technique.
Studies are needed on long-term maintenance therapy and therapies to improve upper extremity function. Strategies to reinforce comprehensive rehabilitation from the facility to the community setting need to be developed. We need more knowledge about how to integrate rehabilitation efficiently across the MS continuum in order to promote independence and social participation. Clinicians need to know when to intervene and how to reinforce positive outcomes in the community. Promising strategies need to be studied in representative groups with adequate sample sizes powered to measure change, using multicenter trials.
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DISCLAIMER
Clinical practice guidelines, practice advisories, systematic reviews, and other guidance published by the American Academy of Neurology and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information: (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. AAN provides this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.
